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Abstract: Adenine nucleotides, ADP and ATP, are coreleased from dense granules during platelet activation, as well as
from endothelial cells and damaged red blood cells following vascular injury. Through autocrine and paracrine mecha-
nisms, these extracellular signaling molecules interact with the platelet P2 receptors to amplify ongoing platelet activation.
Two receptors for ADP, the Gq-protein-coupled P2Y1 and G i-protein-coupled P2Y12 and one receptor for ATP, the P2X1
ion channel, have been identified on platelets. Due to distinct pharmacological properties and differential regulation, the
P2Y and P2X receptors essentially operate on different scales of time and distance and trigger selective intracellular sig-
naling cascades. Recent advances in the understanding of the P2Y receptor physiology have reinforced the concept of
these receptors as useful targets for antithrombotic therapy. The function of P2X1 in platelet activation only recently
started to be unraveled. This review focuses on recent findings on the physiology of these platelet ADP and ATP recep-
tors, their distinct downstream intracellular signaling pathways as well as on the available agonists, antagonists and in-
hibitors that allow their pharmacological discrimination.
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HISTORY AND CLASSIFICATION OF PURINERGIC
RECEPTORS
The first report about the potent actions of an adenine
compound, AMP, extracted from heart muscle, was pub-
lished by Drury and Szent-Györgyi in 1929. Initial investi-
gations focused on effects of adenosine and ATP on the heart
and vasculature, or concerned the effects of purines on
platelets [1] and on mast cells. Further insights into the
physiological role of extracellular purines and pyrimidines
were provided via the study of their biological sources [2]. In
this respect, the detection of nucleotide release from the
heart during hypoxia [3] or from skeletal muscle during
contraction indicated that secretion of purine compounds
might be coupled to metabolic demand to regulate local
blood flow. ATP release from sensory nerves suggested that
adenine nucleotides play a role as neurotransmitter or neu-
romodulator in the central and peripheral nervous system [4].
These early publications established that purinergic nu-
cleotides act as extracellular signaling molecules [5]. Nu-
cleotides are now documented to contribute to a diverse
range of physiological responses such as smooth muscle
contraction, neurotransmission, exocrine and endocrine se-
cretion, immune response, inflammation, platelet aggrega-
tion, male reproduction, nociception and modulation of car-
diac function [6].
Purines and pyrimidines mediate their effects by inter-
acting with distinct cell-surface receptors. Purinergic recep-
tors were first formally recognized by Burnstock in 1978 [7].
They were divided into two classes: at P1-purinoceptors
adenosine is the principal natural ligand, while P2-purino-
ceptors recognize both purine and pyrimidine nucleotides
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[8], namely ATP, ADP, UTP and UDP. P1 receptors are
further divided into four subtypes (A1, A2A, A2B, A3) and
all couple to G proteins [9].
Based on an increasing amount of experimental data con-
cerning signal transduction mechanisms, pharmacological
response profiles, desensitization kinetics, tissue distribution
and biological effects obtained during the 80-90s, the exten-
sive and heterogeneous group of P2 receptors was subdi-
vided into P2X ligand-gated cation channels and G protein-
coupled P2Y receptors [10]. This classification was based
almost exclusively on the potency of purine and pyrimidine
nucleotides to act as P2 agonists, but it is now known to co-
incide with the molecular structure and signal transduction
mechanism of the underlying receptors, and has been re-
tained.
The possible pitfalls of agonist-based receptor classifica-
tion are well known and are very relevant to the P2 receptor
area. Errors can occur because many nucleotides are metab-
olically unstable and are degraded by the ecto-nucleotidases
present on cells [6]. In addition, ectonucleoside-diphospho-
kinases on many cells can convert dinucleotides into trinu-
cleotides, making assessment of ADP and UDP activities
difficult [11]. Release of endogenous nucleotides may also
introduce problems, due to desensitization and down-
regulation of the P2 receptor-promoted signaling response
[11]. Finally, the presence of contaminating nucleotides in
commercial nucleotide sources can produce misleading ef-
fects on the observed drug selectivity profiles at P2 receptor
subtypes [12, 13].
THE PLATELET P2Y1 AND P2Y12 RECEPTORS FOR
ADP
Intracellular Signaling Pathways
ADP signaling is often required to complete platelet ag-
gregation. It is released from dense granules in response to
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agonist stimulation and can synergize with other agonists to
activate platelets [14, 15]. ADP produces platelet shape
change and induces platelet aggregation by converting the
platelet fibrinogen receptor, integrin a IIbb3, to an active con-
formation. The ability of ADP to trigger secretion from
platelets is controversial and may depend on the presence of
Ca2+ in the medium [16].
Platelets possess at least two P2Y receptors whose com-
bined action is required for full activation and aggregation in
response to ADP [17-23] (Fig. 1). One of these, P2Y1, is
coupled to the heterotrimeric GTP-binding protein Gq and to
phospholipase C-b  activation; it induces mobilization of
cytoplasmic Ca2+ and mediates shape change followed by an
initial wave of rapidly reversible aggregation. Whether it
also leads to stimulation of Rho/Rho kinase via Ga12/13 is
unclear [24]. Nevertheless, the study by Paul et al. [25] indi-
cates that both Ca2+/calmodulin-stimulated myosin light
chain kinase and p160 Rho-associated coiled-coil-containing
protein kinase independently contribute to ADP-induced
myosin light chain phosphorylation and to platelet shape
change, through Ca2+-sensitive and Ca2+-insensitive path-
ways, respectively. It was also described that P2Y1 mediates
p38 mitogen-activated protein kinase (p38MAPK) activa-
tion, an event requiring an aspirin-sensitive cofactor [26];
however, the functional significance of this signaling cas-
cade in platelets and the downstream target of this kinase are
not known.
The other receptor, P2Y12 [27], is negatively coupled to
adenylyl cyclase through Gi; it mediates progressive and
sustained platelet aggregation in the absence of shape change
and plays an important role in the potentiation of secretion
induced by several agonists via its interaction with released
ADP. This process is independent of the formation of large
aggregates and of thromboxane A2 synthesis [28, 29]. P2Y12-
mediated activation of the phosphoinositide 3-kinase (PI 3-
K) pathway contributes to stabilize thrombin-induced plate-
let aggregates [30], although thrombin and thrombin-related
peptides can cause platelet aggregation independently of Gi
signaling [31]. The concurrent activation of the Gq and Gi
pathways during full platelet aggregation is highlighted by
the observation that normal aggregation responses to ADP
can be restored in P2Y12-deficient platelets by adrenaline,
which is negatively coupled to adenylyl cyclase through Gz
[32]; likewise, serotonin, which is coupled to Gq, can sub-
stitute for ADP in P2Y1-null mouse platelets [33, 34]. How-
ever, from studies performed on Gaq-deficient murine
platelets, it appeared that the activation of G12/G13- and Gi-
mediated pathways by the thromboxane A2 mimetic and
ADP, respectively, is sufficient to induce a IIbb3 activation
[35]. This indicates that the efficient induction of platelet
aggregation through G-protein-coupled receptors is an inte-
grated response triggered by various converging G-protein-
mediated signaling pathways involving Gq, Gi as well as
G12/G13. Of interest is the observation that high ADP con-
centrations are able to induce partial a IIbb3-dependent aggre-
gation without shape change for P2Y1-null mouse platelets,
through P2Y12-mediated PI 3-K activation [36]. Such aggre-
gation was strongly potentiated by adrenaline.
The small GTPase Rap1B is activated by ADP through
both G i- and PI 3-K-dependent and Gq- and Ca
2+-dependent
mechanisms, which eventually may promote aIIbb3 activation
[37]. In this respect, Larson et al. [38] have recently shown
that the collagen receptor GPVI-mediated Rap1 activation
largely depended on ADP signaling through P2Y12, but not
through P2Y1. In the same context, another study showed
that, during thromboxane A2 mimetic-induced platelet ag-
gregation, signaling through the P2Y12 receptor by secreted
ADP causes positive feedback on platelet secretion through a
PI-3 kinase pathway [39]. Thus, P2Y12-mediated PI 3-K ac-
tivation seems to be instrumental during platelet aggregation
triggered by most platelet agonists (Fig. 1). Finally, a recent
study shows an essential role for P2Y12/Gi signaling path-
ways, via secreted ADP, in activating the PI 3-K-dependent
serine-threonine kinase Akt during platelet responses to
thrombin, PAR1- or PAR4-activating peptides [40].
Pharmacology
The order of potency for agonist stimulation of P2Y1 is 2-
methyl-thio-ADP (2MeS-ADP) >> ADP = ADPaS >
ADPbS and of P2Y12 is 2MeS-ADP >> ADP = ADPbS;
ADPaS is an antagonist at P2Y12. Structure-activity studies
have previously been reviewed extensively [14, 41]. ADP
receptor numbers have been quantified with radiolabeled
2MeS-ADP, which binds to between 500 and 1000 sites per
platelet [29, 42-44]. Evaluation of P2Y1 binding sites is en-
abled by studies performed under conditions in which one
receptor is blocked or absent. In the two well-characterized
patients lacking P2Y12, the number of 2MeS-ADP binding
sites fell to about 30 for one patient [42] and to about 170 for
the other [43]. These low values fit with the difficulties to
detect P2Y1 in flow cytometry by using available antibodies;
in the P2Y12-deficient SP1999 mouse model, no specific
binding for 2MeS-ADP could be measured [45]. In fact, a
recent study [46] described the existence of internal mem-
brane pools of P2Y1 receptors, on membranes of a-granules
and of the open canalicular system (OCS), and on a network
of thin channels that ramify from the surface into the interior
of the platelet. Although the functional significance of the
internal pools is unknown, pharmacological antagonism of
ADP during antithrombotic therapy may need to take into
account blockade of such internal receptor pools.
Platelets treated with ADPbS become refractory to ADP
stimulation [47]; this platelet refractory state was entirely
due to desensitization of the P2Y1 receptor, the P2Y12 re-
ceptor remaining functional. The decrease in [33P]2-
MeSADP binding sites measured on refractory platelets cor-
responded to the disappearance of the P2Y1 sites with no
change in the number of P2Y12 sites, suggesting internaliza-
tion of P2Y1. This was confirmed by flow cytometric analy-
sis of Jurkat cells expressing an epitope-tagged P2Y1 recep-
tor, where ADPbS treatment resulted in complete loss of the
receptor from the cell surface. It was concluded that the
P2Y1 and P2Y12 receptors are differently regulated during
platelet activation.
The P2Y1 Receptor
The P2Y1 receptor was the first P2Y to be cloned and
identified as a metabotropic receptor for adenine nucleotides
[47]. Since its discovery, many more P2Y receptor subtypes
have been identified [48] and the current series now extends
to P2Y13 [49]. P2Y1 couples to heterotrimeric G proteins
(Gq/Ga11) and, through this link, stimulates phospho-
The Platelet ATP and ADP Receptors Current Pharmaceutical Design, 2005, Vol. 11, No. 00    3
inositide turnover and release of intracellular calcium. Hu-
man P2Y 1 is particularly sensitive to ADP and 2MeS-ADP;
whether ATP is an agonist of P2Y1 is highly controversial
and may depend on receptor expression levels. The tissue
distribution for P2Y1 protein, and messenger RNA, is ubiq-
uitous –found in peripheral sensory nerves and central nerv-
ous system, most physiological systems and many cell types
including blood platelets. P2Y1-deficient mice [33, 34] dis-
played impaired platelet aggregation and increased resistance
to pulmonary thromboembolism induced by infusion of a
mixture of collagen and adrenaline. Also, using tissue factor
(TF) to promote thrombin dependent thromboembolism,
these mice exhibited higher thromboresistance and a signifi-
cantly reduced in vivo thrombin generation [51]. These ob-
servations have led the authors to present the platelet P2Y1
receptor as a potential target for antithrombotic therapy.
The 2-Chloro-N6-methyl-(N)-methanocarba-2’ deoxy-
adenosine-3’, 5’-biphosphate (MRS 2279) developed in the
Molecular Recognition Section (NIH, Bethesda, MD) is a
potent highly selective and competitive antagonist for the
P2Y1 receptor with a Kd value of 9 nM at the platelet receptor
[52, 53]. This antagonist provides the means to study the
physiological role of native P2Y1 receptors. MRS 2279
potently inhibits ADP-induced aggregation of human plate-
lets in vitro , although the current utility of the compound is
limited to being a research tool, not an antithrombotic agent.
The origins of this compound can be traced back to work on
the inhibitory actions of simple bisphosphate nucleotides
(e.g. adenosine 3’-phosphate 5’-phosphate) at the P2Y1 re-
ceptor - where these agents acted as competitive, yet not
especially potent, antagonists [ 54 ] . Others drew attention to
the “limited subtype specificity and non-P2 receptor effects”
of such bisphosphate nucleotides [55, 56]. The next land-
mark compound was MRS 2179 (N6-methyl 2’-deoxy-
adenosine 3’, 5’-biphosphate), another competitive antago-
nist at the P2Y1 receptor [57-60]. But hopes for MRS2179
were dashed following observations of inhibitory activity for
this compound at recombinant P2X1 and P2X3 receptors [61].
Thereafter, the focus switched to non-ribose compounds
Fig. (1). Current model of platelet purinergic receptors. Two receptors for ADP, P2Y1 coupled to Gq and P2Y12 coupled to Gi, and one re-
ceptor for ATP, the P2X1 ion channel, contribute to platelet activation. Inhibitors or antagonists of P2Y12 are useful antithrombotic drugs.
Selective P2Y1 antagonists that inhibit platelet function in vitro also exist. Compounds acting as selective and highly potent antagonists at the
recombinant P2X1 receptor are shown. Whether these compounds are able to inhibit P2X1–dependent events in platelets largely remains to be
investigated. Nothing is known on the ability of NF279 and NF449 to antagonize the platelet P2X1 receptor.
4    Current Pharmaceutical Design, 2005, Vol. 11, No. 00 Oury et al.
where the ribose moiety was substituted by methanocarba
pseudosugars in either Northern (N) or Southern (S) confor-
mations – to reduce the flexibility of the sugar spacer and
enhance ligand docking. The resultant MRS 2279 represents
the most potent and selective compound of this series of
analogues, as reported by Boyer et al. [52]. Full understand-
ing of the pharmacology of MRS 2279 will depend on its
commercial availability. As yet, MRS 2279 has not been
tested on recombinant P2X receptors. Also, no mention is
made of its (in)activity at adenosine receptors. The chemical
structures of these P2Y1 antagonists have been presented in a
recent review [15].
The P2Y12 Receptor
In contrast to the ubiquitous expression of P2Y1 [62],
P2Y12 expression is restricted to platelets and the brain [27,
63]. The intronless genes for P2Y1 and P2Y12 receptors are
co-localized on chromosome 3q21-q25 [64] and share 22%
sequence identity [27, 62]. P2Y12 is the therapeutic target of
ticlopidine and clopidogrel, two platelet aggregation inhibi-
tors used for prevention and treatment of arterial thrombosis
[65, 66]. Clopidogrel (SR25990C, PLAVIX) is a potent anti-
aggregant and antithrombotic drug, as demonstrated in sev-
eral experimental models of thrombosis [67]. The drug was
launched on the market following a successful clinical
evaluation and demonstration of superior efficacy versus
aspirin in preventing thrombotic events (myocardial infarc-
tion, stroke, and vascular death) in high risk patients
(CAPRIE Steering Committee, 1996). Clopidogrel adminis-
tered in vivo  selectively and irreversibly inhibits the binding
of 2MeS-ADP to platelet P2Y12 [68-70]. Clopidogrel is in-
active in vitro and has to undergo metabolic activation by
hepatic cytochrome P450-1A [71, 72]. A possible metabolic
pathway leading to the formation of the active metabolite of
clopidogrel was tentatively deduced [73]. In the liver, clopi-
dogrel is metabolized into 2-oxo-clopidogrel. This interme-
diate is then hydrolyzed and generates the highly labile ac-
tive metabolite, which reacts as a thiol reagent with P2Y12 on
platelets when they pass the liver. This in situ biological ef-
fect could account for the absence of an antiaggregating ac-
tivity in the plasma. In a recent work [74], the occurence of
an in vitro active metabolite was documented after incuba-
tion of 2-oxo-clopidogrel with human liver microsomes.
Mass spectrometry results suggested that the active metabo-
lite belongs to a family of eight stereoisomers with the fol-
lowing primary chemical structure: 2-{1-[1-(2-chlorophe-
nyl) - 2 - methoxy - 2 - oxoethyl] - 4 - sulfanyl - 3 - piperidinylidene }
acetic acid. However, only one of the eight metabolites re-
tained biological activity, underlining the critical importance
of the associated absolute chemical configuration. The active
metabolite would be of S configuration at C 7 and Z configu-
ration at the C 3-C 16 double bond.
The active metabolite of clopidogrel, containing a free
thiol group, inactivates P2Y12 through formation of a disul-
fide bridge with extracellular cysteine residues [69, 73, 75].
Another antiplatelet drug, CS-747, neutralizes P2Y12 by the
same mechanism [76, 77]. P2Y12 also is irreversibly antago-
nized by the thiol reagent pCMBS [69, 78]. By using site-
directed mutagenesis analysis, Ding et al. [79] have identi-
fied two free cysteine residues in the P2Y12 extracellular
domain (C17 and C270) to be the targets for thiol reagents.
They proposed that the lack of these free cysteines in the
extracellular domain of P2Y1 explains why this receptor is
not inhibited by thiol reagents and by the active metabolites
of clopidogrel or by CS-747.
Since ticlopidine and clopidogrel are prodrugs requiring
metabolization, inhibition of platelet aggregation by these
drugs is delayed until 24-48 h after administration, with
maximal inhibition achieved after 3-5 days [65]. Recovery of
platelet function after drug withdrawal is slow (7-14 days).
Ticlopidine and clopidogrel are effective in preventing
atherothrombotic events in cardiovascular, cerebrovascular
and peripheral vascular disease. However, neutropenia and
thrombotic thrombocytopenic purpura are significant and
occasionally fatal adverse effects of ticlopidine. Clopidogrel
appears to offer several advantages over ticlopidine: a more
rapid onset of action and lower incidence of the adverse ef-
fects. A combination of clopidogrel and aspirin has become
standard antithrombotic therapy in a few cardiovascular con-
ditions (e.g. following stent placement). The pharmacology
and clinical developments of the thienopyridine derivatives
have been recently reviewed [65].
Competitive P2Y12 antagonists are also being developed
[80, 81]. Modification of the polyphosphate side chain of
ATP to prevent breakdown to ADP and substitution of the
adenine moiety to enhance affinity and selectivity for the
P2Y12 receptor led to the identification of 2-propylthio-b , g -
dichloromethylene ATP (AR-C67085MX) [80], having an
IC50 of 2.5 nM against ADP-induced aggregation of human
platelets. This compound was the first very potent competi-
tive antagonist of the P2Y12 receptor, with a selectivity for
that subtype of the P2 receptor family of > 1000-fold. Fur-
ther modification of the structure produced N6-(2-methyl-
thioethyl)-2-(3, 3, 3-trifluoropropylthio)-b , g -dichloromethy-
lene ATP (AR-C69931MX) with an IC50 of 0.4 nM [80]. In a
canine model of arterial thrombosis, AR-C69931MX was
found to antagonize the ex vivo  and in vivo  aggregatory ac-
tions of ADP, and to display a rapid onset and offset of ac-
tion with the ability to prevent occlusive arterial thrombus
formation [82]. This compound also sustains canine coronary
artery recanalization and improves myocardial tissue perfu-
sion [83]. It therefore may be suited for the management of
patients who require short-term modulation of platelet func-
tion. AR-C69931MX currently is in phase II clinical trials
for the treatment of acute coronary syndromes.
Chemical stuctures of the P2Y12 antagonists and inhibi-
tors are depicted in the recent review by Gachet [15].
Congenital Defects of P2Y12
Congenital deficiency of P2Y12 results in a bleeding dis-
order. Four patients with abnormalities of platelet function
due to a severe defect of P2Y12 have been described so far
[29, 42, 84, 85]. In common, these patients have a lifelong
history of mucosal bleeding, easy bruising and/or excessive
post-operative bleeding, mildly to severely prolonged
bleeding times, weak and rapidly reversible primary wave of
aggregation induced by ADP and abnormalities of platelet
aggregation induced by collagen, arachidonate and throm-
boxane A2 analogues, but normal aggregation induced by
high concentrations of thrombin. Platelets deficient for this
receptor exhibit normal ADP-induced shape change but ADP
The Platelet ATP and ADP Receptors Current Pharmaceutical Design, 2005, Vol. 11, No. 00    5
fails to inhibit the rise in cAMP levels after stimulation with
prostaglandin E1 [86]. The P2Y12 defect is inherited as a
autosomal recessive trait [86], and heterozygous patients
display a mild abnormality in platelet function similar to that
seen in the relatively common primary secretion defects.
The genetics of P2Y12 defects have been investigated. In
two instances, different homozygous frameshift mutations
were found to cause premature termination of translation. In
another case, one allele presented a reading frame shift
caused by the deletion of two nucleotides, whereas the other
case had a normal coding sequence but a reduced expression,
possibly resulting from another mutation in a regulatory re-
gion of the gene [27]. In a recent report [85], the patient was
a compound heterozygote for two distinct amino acid sub-
stitutions that independently impair all the responses medi-
ated by P2Y12 without affecting ADP binding.
Role of the ADP Receptors in Coagulation
While the ADP pathway is recognized to enhance throm-
bus formation by recruiting platelets and leukocytes to the
primary layer of collagen-adhering platelets, its role for the
initiation of coagulation has not been revealed.
The platelet P2Y1 and P2Y12 receptors both contribute to
thrombosis and thrombin formation in an in vivo model of
TF-induced thromboembolism [51]. The P2Y12 receptor, but
not P2Y1, was also found to be involved in thrombin-induced
exposure of phosphatidylserine on isolated platelets and in
TF-induced thrombin formation in platelet-rich-plasma [87].
Both receptors contribute to the interaction between platelets
and leukocytes mediated by P-selectin exposure, and result-
ing TF exposure at the surface of leukocytes [87].
A recent study [88] shows that ex vivo inhibition of the
P2Y12 ADP receptor by clopidogrel administration dimin-
ished the rapid exposure of TF in conjugates of platelets with
leukocytes established by the contact of whole blood with
fibrillar collagen. In in vitro conditions, the P2Y12 and P2Y1
ADP receptors were both found to be implicated in the expo-
sure of TF in collagen-activated whole blood. Immunoelec-
tron-microscopy revealed that collagen elicited the release of
TF from its storage pools within the platelets. Functional
activation of the intravascular TF was reduced by inhibition
of the ADP receptors, partially due to the disruption of the
platelet-neutrophil adhesions. Injection of collagen into the
venous circulation of mice increased the number of throm-
bin-antithrombin complexes, indicative for the formation of
thrombin in vivo . In P2Y1-deficient mice, the ability of col-
lagen to enhance the generation of thrombin was impaired.
This study indicate that the platelet ADP pathway supports
the initiation of intravascular coagulation, which is likely to
contribute to the concomitant formation of fibrin at the site
of the growing thrombus.
THE PLATELET P2X1 RECEPTOR FOR ATP
The Family of P2X Receptors
Seven distinct P2X subunits (P2X1-P2X7) assemble to
form homo- or heteromeric non-selective ATP-gated cation
channels composed of at least 3 monomers; these have been
cloned from mammalian cell types and characterized phar-
macologically by patch clamp electrophysiological meas-
urements in heterologous expression systems [reviewed in
89, 90]. Their overall characteristics and functional proper-
ties closely resemble those in native tissues.
The pharmacological and biophysical properties allow the
receptors to be classified into three groups, which corre-
spond in broad terms to the three phenotypes described for
the native receptors.
The first group comprises the P2X1 and P2X3 receptors;
they are both highly responsive to the specific, non-
hydrolyzable, stable P2X analogue, a,b- meATP as well as
to ATP, and their desensitization is rapid (P2X1 has a time
constant of about 100 to 300 ms, P2X 3 desensitization is best
fit by two exponentials of about 50 ms and 1 s).
The second group comprises the P2X2, P2X4, P2X5, and
P2X6 receptors. In all these cases, a,b- meATP is ineffective
and the receptor desensitization rate is slow. These receptors
can be further subdivided according to their antagonist sensi-
tivity: P2X2 and P2X5 receptors are reversibly inhibited
 by
PPADS and suramin (<30 µM) (Fig. 2), while P2X4 and
P2X6
 receptors are not blocked by this concentration of
PPADS and suramin.
The third distinct type of functional response is exhibited
by the P2X7 receptor. It has a 240 amino acid longer intra-
cellular C-terminus than other P2X receptors. P2X7, cloned
from rat macrophages and brain, is the cytolytic P2 receptor
previously described in mast cells, fibroblasts and macro-
phages. Receptor distribution is generally limited to he-
mopoietic bone marrow cells including granulocytes, mono-
cytes, macrophages, B-lymphocytes, erythrocytes and
erythroleukemia cells. The unique feature of cloned and en-
dogenous P2X7-like
 receptors is that, whereas under physio-
logical conditions they are selectively permeable only to
small cations, in the continued presence of ATP and when
divalent cation levels are low, the cation channel can convert
to a pore, that is permeable to larger molecules upto
900 daltons in addition to ions. This effect is associated with
cytotoxicity. Currents evoked at recombinant P2X7 and en-
dogenous P2X7-like receptors do not readily desensitize.
Subunit Topology
Although the three-dimensional structure of the P2X
subunits is not known, the absence of a leader sequence and
their hydrophobicity pattern predict that they have two
transmembrane domains, placing a large protein loop outside
the cell [91] (Fig. 1).
The different P2X subunits vary between 379 and 595
amino acids in length and share an overall sequence identity
ranging from 35% to 48%. The extracellular loop of P2X
channels is highly glycosylated; in the P2X2 channel, glyco-
sylation occurs at three asparagine residues (N182, N239 and
N298) and deletion of any two out of the three leads to non-
functional channels [92].
Based on structural similarities with the mechanosensi-
tive channels of the MscL class, the amino- and carboxy-
terminal tails of P2X subunits might be close to each other,
sitting beneath the channel pore in a closed state. This
stoichiometry may explain how truncations, deletions, muta-
tions and splicing in these regions greatly affect the kinetics,
permeation and desensitization of the channels [90]. In
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NF023:  R1 = H,  X = 0
NF279:
SURAMIN:  R1 = CH3,  X = 1
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addition, these intracellular regions are clearly important, but
not the sole determinants of receptor function, as expected
for allosteric proteins. The possibility that the long carboxy
tail of P2X receptors interacts with other proteins has been
suggested; interaction of P2X7 channels with several cy-
toskeletal proteins has been demonstrated [93].
Using disulfide bond formation between engineered cys-
teines, a recent study demonstrated close proximity between
the outer ends of the first transmembrane domain of one
subunit and the second transmembrane domain of another
[94]. In the hetero-oligomeric P2X2/P2X3 receptor, the coex-
pression in HEK293 cells of doubly substituted subunits with
wild-type partners revealed that the hetero-oligomeric chan-
nel contains adjacent P2X3 subunits but does not contain
adjacent P2X2 subunits. This study suggests a “head-to-tail”
subunit arragement in the quaternary structure of P2X re-
ceptors and show that a trimeric P2X2/P2X3 receptor would
have the composition P2X2(P2X3)2.
The ATP-binding site of P2X receptors is thought to be
located within the cysteine-rich extracellular loop, because
ATP gates P2X receptors when applied extracellularly. In
addition, purified extracellular loops obtained from P2X2
subunits bind ATP [95]. P2X receptors do not contain con-
sensus motifs common to other ATP-binding proteins. Inter-
estingly, alterations in ATP potency were easily produced by
mutagenesis of many residues [90]. Systematic analyses of
the extracellular loop indicate that positively charged resi-
dues (K68 and K70, R292 and K309) in this region form part
of the channel vestibule and contribute to the binding of the
terminal phosphate of ATP in P2X subunits [96]. Accord-
ingly, a recent study in Xenopus oocytes revealed that
among the 20 conserved aromatic amino acids located in the
extracellular ligand binding loop of P2X1, residues K68,
F185, F291, R292 and K309 contribute to ligand binding,
with F185 and F291 co-ordinating the binding of the adenine
ring of ATP [97].
Combined mutagenesis and pharmacological studies have
suggested that the non-specific P2 antagonist PPADS binds
to the same site as ATP, whereas other classes of P2 antago-
nists, like suramin, have a different binding site within the
extracellular loop  [98, 99] (Fig. 2). These observations indi-
cate that other binding sites in addition to the ATP site exist,
modulate receptor function and probably might be targeted
selectively with different drugs.
Desensitization of P2X Receptors
P2X receptors were divided into two broad groups ac-
cording to current desensitization i.e. returning to zero rap-
idly (within 100 to 300 ms), or slowly if at all. The rapid
desensitization of the ion currents should not be confused
with receptor “desensitization”, which occurs over a few
seconds and reflects the inability of the receptor to respond
to subsequent agonist application. Desensitization clearly
serves to terminate the purinergic response even though ATP
still is present in the environment.
The molecular mechanism of P2X receptor desensitiza-
tion is not well understood. For the rapidly desensitizing
P2X1 receptor, this may
 involve the hydrophobic domains of
the receptor because in P2X1-P2X2 chimeras, transfer
 of the
P2X1 hydrophobic domains, but not the extracellular loop of
the P2X1 receptor changes the phenotype
 of the P2X2 recep-
tor from non-desensitizing to rapidly-desensitizing [100].
Accordingly, a P2X1-P2X2 chimera containing the entire
P2X1 extracellular domain shows the non-desensitizing
property of P2X2 [101]. The N-terminal region
 of the P2X3
receptor has been suggested to be important in the desensiti-
zation process. Desensitization of the  P2X3 receptor seems to
involve the activation of calcineurin through the entry of
extracellular calcium [102].
Regulation of Channel Function
Similarly to other neurotransmitter-gated channels, pro-
longed agonist stimulation results in changes in the surface
localization of P2X receptors. P2X1 receptors tagged with
green fluorescent protein are rapidly internalized following
agonist stimulation [103]; native P2X1 receptors were also
internalized in smooth muscle [104]. However, this phe-
nomenon, probably involving cytosolic factors, does not
explain the rapidly desensitizing phenotype of the P2X1-
mediated currents. It remains to be determined whether other
P2X receptors are similarly internalized and how this
mechanism affects the regulation of P2X receptor-mediated
responses in native cells.
All P2X subunits contain a consensus protein kinase C
(PKC) phosphorylation site (Thr-X-Lys/Arg) in the amino-
terminal tail. PKC-mediated threonine phosphorylation was
shown to preserve the slowly desensitising property of the
P2X2 channel
 [105]. Disruption of this residue leads to ab-
sent phosphorylation of the protein and simultaneously con-
verts the ion current to the rapidly desensitizing phenotype.
The same Thr residue is essential in P2X3 channel function
since, when replaced by Ala, the channel became inactive.
Moreover, this site has been shown to be responsible for the
PKC-mediated potentiating effect of inflammatory mediators
on P2X3 channel function, probably explaining the ability of
these mediators to modulate nociception  [106]. In transfected
HEK293 cells, the absence of P2X1 phosphorylation on resi-
due T18 abolishes the ATP-induced inward current. Moreo-
ver, mutating residue R20 into T20 leads to absence of phos-
phorylation on residue T18 [107]. A recent study reported
that in the slowly-desensitizing P2X7 channel, phosphoryla-
tion of a single tyrosine residue at position 343 is required to
maintain the run-down of the current as well as to sustain the
interaction of P2X7 with several, mainly cytoskeletal pro-
teins, resulting in formation of a signaling complex [94].
These observations suggest that phosphorylation of the con-
served PKC site serves as effective regulator of the channel
function.
Using site-directed mutagenesis, we have investigated the
function of the four highly conserved intracellular tyrosine
residues of the P2X1 ion channel [108] (Fig. 3). Simultane-
ous electrophysiological and calcium measurements in trans-
fected human embryonic kidney (HEK293) cells indicated
that Y362F and Y370F mutants were non-functional, despite
their proper plasma membrane expression. The Y16F and
Y363F mutants retained 2.2 % and 26 % of the wild-type
P2X1 activity, respectively. However, no tyrosine phos-
phorylation was detected on Western blots of P2X1 immuno-
precipitates derived either from HEK293 cell lysates or from
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human platelets, with or without stimulation of the receptor.
Thus, we concluded that Y16, Y362, Y363, and Y370 are
required for the appropriate three-dimensional structure and
function of the intracellular P2X1 domains, independently of
their phosphorylation.
Extracellular cations modulate ATP-activated currents in
cloned and endogenous P2X receptors. Mg2+ and Ca2+ gener-
ally inhibit P2X receptor currents, probably by decreasing
the affinity of the ATP binding site via an allosteric modula-
tion in the receptor. Interestingly, the recombinant P2X1 re-
ceptor seems to be less susceptible to inhibition by increases
in extracellular Ca2+ [109]; Zn2+ potentiates the cation con-
ductance induced by ATP at most P2X receptors, including
recombinant P2X1.
Modulation of the affinity of the ATP-binding site also
occurs by extracellular protons; acid pH causes an increase,
and alkaline pH causes a decrease in currents [110]. This
may be particularly significant for P2X receptor-mediated
signaling in pathophysiological conditions where injury or
inflammation can alter the extracellular pH.
The P2X1 Receptor
The P2X1 receptor has been first cloned from rat vas
deferens and human and mouse urinary bladder [111, 112].
The P2X1 receptor encoding gene contains 12 exons span-
ning 20 kilobases on chromosome 17p13.2. P2X1 receptor
mRNA is expressed in urinary bladder, vas deferens, smooth
muscle layers of small arteries and arterioles, with lower
levels in spinal cord and rat brain, in lung and spleen and
finally in dorsal root, trigeminal and coeliac ganglia [90,
111]. There is a prominent variation in the size of transcripts
expressed in different tissues. The regulatory processes un-
derlying tissue specific expression of the P2X1 gene are un-
known except for an E box response element that binds a
b helix-loop-helix protein and contributes to smooth muscle
specific transcriptional regulation [113].
Pharmacology
The recombinant receptor is activated by 2MeSATP 
ATP > a,b- meATP, and inward currents evoked by these
compounds are reversibly blocked by suramin, PPADS [110]
and are very sensitive to inhibition by TNP-ATP (IC50 about
1 nM)  [114] (Fig. 2). Suramin analogues showing selectivity
for P2X1 receptors have been synthetized and characterized
pharmacologically: one such compound is the symmetrical
3’-urea of 8-(benzamido)naphtalene-1, 3, 5-trisulfonate
(NF023) [115] (Fig. 2). NF023 is wholy selective for P2X1
receptors in studies with the cloned receptor expressed in
Xenopus oocytes, being weak at recombinant P2Y1 (pIC50=
4.6). A series of second generation suramin analogues with
4’-aminobenzoyl-linkages of one or two phenyl rings have
been evaluated. One of these compounds, NF279, was the
subject of a more detailed pharmacological investigation
[116]. In prostatic segments of the rat vas deferens, NF279
(0.3-3 m M) inhibited the contractions evoked by a,b -
meATP. A physiological role for P2X1 receptors in renal
microvascular autoregulatory behavior has been described
[117]. Afferent arterioles from rats and P2X1-deficient mice
(see below) were examined using the juxtamedullary neph-
ron technique. Pressure-mediated vasoconstriction were
measured before or during P2X1 receptor blockade with
Fig. (3). Sequence alignment of human P2X receptors. Conserved tyrosine residues are boxed with solid lines and partially conserved resi-
dues with dashed lines. P2X1 transmembrane domains (TM1 and TM2) are overlined with a bar.
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NF279. This compound as well as deletion of P2X1 receptors
attenuated the autoregulatory response induced by an in-
crease in renal perfusion pressure. NF279 was also a highly
potent P2X1-selective antagonist (IC50=0.02-0.05 m M) in
studies with cloned receptors expressed in Xenopus oocytes
[118]. This compound was found to be weak at recombinant
P2Y1 (pIC50=4.6) and inactive (up to 100 m M) at P2Y2,
P2Y4, and P2Y6 receptors.
The antagonistic effects of the novel suramin analogue
4, 4', 4", 4"'-(carbonylbis(imino-5, 1, 3-benzenetriylbis(car-
bonylimino)))tetrakis-benzene-1, 3-disulfonic acid (NF449)
[119] (Fig. 2) were analyzed at homomeric human P2X1 and
P2X7 receptor subtypes (hP2X1 and h P2X7) heterologously
expressed in Xenopus oocytes using the two-microelectrode
voltage-clamp technique. At activating ATP concentrations
of 1 microM (hP2X1) and 100 microM (hP2X7), IC50 values
of 0.05 nM and 40 m M were found for hP2X1 and hP2X7
receptors, respectively. The Schild analysis revealed a pA2 of
10.7 at hP2X1. Wash-in and wash-out of 10 nM NF449 were
nearly complete within 16 s and 4 min, respectively, at the
hP2X1 receptor. An increase in the activating ATP concen-
tration to 100 microM shifted the NF449 concentration-
inhibition curve rightwards for the hP2X1 receptor. NF449
decelerated activation as well as desensitization of hP2X1. It
is concluded that NF449 acts as a reversible competitive
antagonist at the hP2X1 with much higher potency at hP2X1
than at hP2X7 receptors. NF449 may hence be excellently
suited to discriminate between both receptors in native hu-
man tissues.
Novel analogues of PPADS have also been developed
and characterized as antagonists at recombinant P2X1, P2X2,
and P2X3 receptors in Xenopus oocytes and turkey erythro-
cyte P2Y1 receptors [120]. From these studies, the compound
MRS2159 was found to be a very potent and selective P2X1
antagonist (IC50=10 nM) (Fig. 2).
L-b,g- meATP proved to be a useful agonist to distin-
guish P2X1 from other P2X receptors. It is a potent agonist at
recombinant P2X1 (EC50=1.9 µM) [121] and induces con-
traction of a variety of smooth muscle preparations via P2X1-
like receptors [122]. In contrast, L- b,g- meATP has been
found to be ineffective at recombinant P2X2
 [121] and P2X4
receptors and at native P2X receptors in a,b- meATP-
responding and non-responding neurons. Furthermore, L-
b,g- meATP is inactive on P2Y receptors mediating relaxant
responses in guinea-pig taenia coli and on native and recom-
binant P2Y receptors from chick brain. It is also resistant to
degradation by ecto-nucleotidases, and its potential break-
down product, L-adenosine, is inactive at P1 receptors.
Activation and desensitization kinetics of the rat P2X1
receptor at nanomolar ATP concentrations were further
studied in Xenopus oocytes using two-electrode voltage-
clamp recording [123]. The authors propose that these low
ATP concentrations obscure P2X1 receptor responses by
driving a significant fraction of the receptor pool into a long-
lasting refractory closed state. The K1/2 of 3.2 nM for recep-
tor desensitization would reflect the nanomolar ATP affinity
of the receptor found by others in agonist binding experi-
ments. The high EC50 value of 0.7 m M for receptor activation
is a consequence of fast desensitization combined with non-
steady-state conditions during recording of peak currents,
which are the basis of the dose-response curve.
In order to study the intrinsic P2X1 receptor kinetics, the
same authors have used a non-desensitizing P2X1/P2X2 chi-
mera comprising the entire P2X1 ectodomain [118]. This
chimera showed a 200- and 7000-fold higher ATP potency
than observed for parent P2X1 and P2X2(A) receptors, re-
spectively. Upon washout, the chimera deactivated slowly
with a time constant t inversely related to the EC50 value of
the corresponding agonist tested, suggesting that deactiva-
tion time courses reflect unbinding rates. The chimera also
possesses virtually identical sensitivity to NF279. Thus, in
agreement with the previous work, this study shows that the
P2X1 ectodomain confers nanomolar ATP sensitivity, which
within the wild type receptor is obscured by desensitization
such that only a micromolar ATP potency can deduced from
peak current measurements, representing an amalgam of
activation and desensitization.
P2X1-Null Mice
The gene for mouse P2X1 was cloned and its genomic
structure defined by sequencing [124]. The gene spans about
10 kb and consists of 12 exons. All splice sites conformed to
the GT-AG motif and the exon-intron boundaries were
largely conserved with other members of the P2X gene fam-
ily so far cloned. A single transcription-starting site was
identified by 5' RACE analysis, 233 bp upstream of the
translation start site. The P2X1 gene maps to the central re-
gion of mouse chromosome 11.
P2X1-deficient mice show reduced male fertility to ap-
proximately 90% [125]. Male mice copulate normally re-
duced fertility results from a reduction of sperm in the
ejaculate and not from sperm dysfunction. In these mice,
contraction of the vas deferens to sympathetic nerve stimu-
lation is reduced by up to 60% and responses to P2X recep-
tor agonists are abolished. These results show that P2X1 re-
ceptors are essential for normal male reproductive function.
 P2X receptor mediated inward currents and contractions
are abolished in bladder smooth muscle from P2X1-deficient
mice [126]. In normal bladder nerve stimulation evoked
contractions with P2X and muscarinic acetylcholine (mACh)
receptor mediated components. In bladder from the P2X1-
deficient mouse the contraction was mediated solely by
mACh receptors. These results indicate that homomeric
P2X1 receptors underlie the bladder smooth muscle P2X re-
ceptor phenotype. This animal model also revealed that ho-
momeric P2X1 receptors underlie the artery smooth muscle
P2X receptor phenotype and contribute approximately 50%
to sympathetic neurogenic vasoconstriction of mouse mes-
enteric arteries [127]. However, from a study examining the
distribution, ontogeny and role of P2X1 receptors in the
smooth muscle of the mouse intestine, bladder, and male and
female reproductive tracts, it appeared that P2X1 receptors
are not expressed throughout all smooth muscles and that
their expression is developmentally regulated [128]. So, a,b -
meATP (100 microM) failed to evoke contractions of the
epididymis, or seminal vesicle and P2X1 receptors did not
contribute to the control of uterine smooth muscle. In con-
trast, in the ileum, a,b -meATP (100 microM) evoked a tran-
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sient relaxation followed by a contraction. These responses
were abolished by the P2 receptor antagonist iso-pyri-
doxalphosphate-6-azophenyl-2'-5'-disulphonate (iso-PPADS)
(30 microM). Accordingly, contractile responses were re-
duced by > 80% in the ileum from P2x1 receptor-deficient
mice.
The use of P2X1-null mice also showed that P2X1
subunits contribute to the properties of heteromeric P2X re-
ceptors in sympathetic neurons [129]. Finally, tubuloglome-
rular feedback signals are coupled to autoregulatory pre-
glomerular vasoconstriction through ATP-mediated activa-
tion of P2X1 receptors [117].
The Platelet P2X1 Receptor for ATP
Following molecular identification of P2X1 as the first
known P2X subunit from rat vas deferens [111], the P2X1
cDNA was also cloned from human platelets and mega-
karyoblastic cell lines [130]. The use of P2X-based degener-
ated primers led to the amplification of a single band of
cDNA from human platelet RNA preparations as well as
from three megakaryoblastic cell lines (Meg-01, K562, and
CMK11-5). Subsequent DNA sequencing confirmed that this
fragment was identical to a region of cloned human urinary
bladder smooth muscle P2X1 receptor. Importantly, no
 addi-
tional homologous clones were obtained, indicating that in
platelets only P2X1 subunits are expressed, forming rapidly
desensitizing non-selective homomeric cation channels.
Western blotting of platelet lysates separated by SDS-PAGE
and probed with anti-P2X1 IgG reveals the expected protein
with a molecular mass of 60 kDa under reducing or non-
reducing conditions. Endoglycosidase treatment results in
altered migration, the reduced protein weight of 45 kDa con-
firms the highly glycosylated nature of the mature protein
[131].
Interestingly, even before molecular cloning of the re-
ceptor, its existence in platelets had been anticipated by
patch clamp techniques and intracellular calcium measure-
ments. Several studies indicated that the extremely rapid
kinetics of ADP- and ATP-mediated increase in intracellular
Ca2+ concentration were consistent with direct opening of a
plasma membrane ion channel in human platelets [132, 133].
More recently, it was specified that ADP/ATP activates a
non-selective inward cation current, which does not involve
a diffusible second messenger. It had also been demonstrated
that the ADP/ATP-gated non-selective cation channel resem-
bles a P2X-type purinoceptor, since the selective P2X-
agonist a,b- meATP activated rapidly desensitizing, non-
selective cation currents in human platelets. Similarly to
platelets, in rat megakaryocytes ATP and the stable, non-
selective ATP-analogue ATP g S activated a rapid, nonselec-
tive cation channel, consistent with P2X-type responses [134,
135]. Interestingly, spontaneously activated single channel
currents in platelets were similar to P2X currents, suggesting
both to be caused by autocrine activation following release of
endogenous nucleotides. The transient, non-selective P2X-
type current under physiological ionic conditions seemed to
be carried mostly by Na+, although P2X1 receptors exhibit
five fold selectivity for Ca2+ over Na+ [111, 135].
The P2X1 receptor was initially thought to be an
ADP/ATP-activated ion channel and therefore to contribute
to platelet responses to ADP. However, this proposal did not
fit with the findings that P2Y-mediated Gq and Gi protein
activation were sufficient to support ADP-induced platelet
aggregation, and that a,b- meATP did not interfere with this
platelet response, which brought doubts on the role of P2X1
in platelet function. In view of the possible pitfalls and arte-
factual results arising from contaminating tri-phosphate nu-
cleotides in commercially available di-phosphate nucleotide
samples, the P2X1 agonist profile was re-examined using
HPLC-purified compounds. It appeared that P2X1 receptor-
triggered ion currents in megakaryocytes were activated by
a,b- meATP and by commercially available ADP, while
HPLC-purified ADP was inactive [136]. This observation
has motivated further analyses of the platelet P2X1 receptor
as an ATP receptor, while ADP would act exclusively at
P2Y1 and P2Y12 receptors. Using HPLC-purified nucleo-
tides, we have further confirmed that ATP is the agonist of
platelet P2X1 receptors at which ADP acts as a weak antago-
nist [137]. Even though the issue of ADP versus ATP as a
P2X1-specific ligand was “reactivated” by the identification
of an alternate P2X1 receptor termed P2X1del (lacking 17
amino acids in the extracellular domain) [138], clear and
definitive evidence now exist that the P2X1del receptor fails
to form functional ion channels and is below the limit of
detection in human platelets and that ATP is the sole P2X1
agonist [139, 140].
Estimations based on transient whole-cell currents indi-
cated a channel density of only 14-34 per platelet [141].
Nevertheless, due to rapid desensitization, a proper evalua-
tion of functional P2X1 receptors is complicated. Im-
munoblot analysis suggests significant, high expression of
the P2X1 protein, strongly maintained during megakaryo-
cytic differentiation and platelet formation [131]. Study of
[3H] a,b- meATP binding on platelets showed only one type
of binding site, its affinity being in the same order of mag-
nitude compared to that reported for ATP receptors in rat
bladder and vas deferens [142]. Scatchard analysis of the
saturation binding data indicated that [3H] a,b- meATP
bound with high affinity (Kd = 23.6 nM). Compared to the
binding of [3H] 2 -MeS-ATP, the number of P2X1 receptors
detected with [3H] a,b- meATP was 4-fold higher, being
evaluated at 4190 ± 150 sites per platelet. 2-MeS-ADP and
ADP competitively inhibited the specific binding of
[3H] a,b- meATP with IC50 values of 103 and 1120 nM, re-
spectively.
Using P2X1-deficient mouse platelets and megakaryo-
cytes [143], the lack of a,b- meATP-induced Ca2+ responses
was demonstrated, further confirming that the P2X receptor
phenotype in megakaryocytes and in platelets is due to ex-
pression of homomeric P2X1 receptors. Interestingly, co-
application in wild-type megakaryocytes of a,b- meATP and
ADP resulted in acceleration and amplification of the peak
Ca2+ response, implying a priming role for P2X receptors in
the subsequent activation of metabotropic P2Y receptors
during platelet stimulation.
We have identified a clonal mutation in the platelet P2X1
receptor of a patient showing a severe bleeding disorder
[144]. This mutation results in deletion of one leucine
residue contained in the second transmembrane (TM2)
domain of this receptor. Voltage-clamped HEK293 cells
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expressing mutated P2X1 channels failed to develop an ATP-
induced current. Furthermore, when co-expressed with the
wild type receptor in Xenopus oocytes, the mutated protein
exhibited a dose-dependent dominant negative effect on the
normal ATP-induced P2X1 channel activity. These data indi-
cate that deletion of a single apolar amino acid residue at the
inner border of the P2X1 TM2 generates a non-functional
channel. The platelet defect of this patient was characterized
by defective platelet secretion and aggregation induced by
low or intermediate doses of collagen, thromboxane A2 mi-
metic, and thrombin-related peptide; the ADP-induced
platelet aggregation were also strongly impaired when ana-
lyzed in the presence of high extracellular Ca2+ concentra-
tions (hirudinized-PRP). Despite of this, the P2Y1 and P2Y12
receptors were found to be normal. The molecular basis of
the platelet defect and the causative link between the P2X1
mutation and the bleeding phenotype are still unclear.
The two stable ATP analogs a , b -meATP and L-
b,g- meATP produce a P2X1-mediated extracellular Ca
2+-
dependent quickly reversible platelet shape change [137,
145]. Recently, it was shown that, by increasing the ex-
tracellular Ca2+ concentration, the P2X1-evoked light trans-
mission decrease (a measure of shape change) reached 82 %
of that obtained via P2Y1 receptors [146]. Despite of this,
following blockade of P2Y1 receptors with A3P5PS, co-
stimulation with a , b -meATP and ADP failed to induce ag-
gregation. Therefore, it appears that the early Ca2+ influx via
P2X1 does not readily synergise with P2Y12 to support ag-
gregation. However, it has been shown that the P2X1 agonist
a,b- meATP potentiates platelet microaggregate formation
when added in conjunction with other weak platelet agonists
such as epinephrine and thrombopoietin [147].
By using a selective P2X1 desensitization strategy, we
found that P2X1 contributes to platelet aggregation induced
by collagen [137]. The ionotropic P2X receptors regulate
intracellular calcium levels through the ligand-stimulated
increase in calcium permeability. However, how these re-
ceptors are linked to intracellular signaling pathways sub-
serving their biological actions still is poorly understood. We
have described that stable P2X1 agonists elicit reversible ex-
tracellular signal-regulated kinase 2 (ERK2) phosphorylation
through a Ca2+-and protein kinase C-dependent pathway
[148] (Fig. 4). Moreover, we have shown that ERK2 activa-
tion caused by low concentrations of collagen exclusively
depends on the P2X1-mediated Ca
2+-influx through early
ATP secretion evoked by this agonist. The P2X1-PKC-ERK2
pathway plays a role in amplifying dense granule release, an
event needed for completion of platelet aggregation upon
mild stimulation with collagen. Furthermore, we found that
a,b -meATP causes rapid, transient (2-5 s), and dose-
dependent myosin light chain (MLC) phosphorylation [149].
Phosphorylation was inhibited by the calmodulin (CaM)
inhibitor W-7, but not by the Rho kinase inhibitor HA-1077,
i.e. it is exclusively regulated by Ca2+/CaM-dependent MLC
kinase. Correspondingly, the P2X1-induced platelet shape
change was inhibited by W-7 and by the MLC kinase in-
hibitor ML-7 but not by HA-1077. W-7, ML-7, the protein
kinase C inhibitor GF109203-X, and the Src family kinase
inhibitor PP1 inhibited the collagen and convulxin-induced
early platelet degranulation, shape change, and subsequent
aggregation, indicating a role for Ca2+/CaM and MLC kinase
in these glycoprotein VI-related platelet responses. The se-
creted ATP-mediated P2X1-dependent ERK2 activation in-
duced by low collagen concentrations contributes to MLC
kinase activation since P2X1 desensitization or blockade of
ERK2 phosphorylation by U0126 strongly attenuated MLC
phosphorylation, degranulation, and aggregation. We there-
fore conclude that at low doses of collagen, glycoprotein VI
activation leads to early protein kinase C- and MLC kinase-
dependent degranulation. Rapidly released ATP triggers
P2X1–mediated Ca2+ influx, activating ERK2, in turn ampli-
fying platelet secretion by reinforcing the early MLC kinase
phosphorylation. Hence, the P2X1-ERK2-MLC axis contrib-
utes to collagen-induced platelet activation by enhancing
platelet degranulation (Fig. 4).
In order to investigate further the role of P2X1 and the
coupled ERK2 in hemostasis and thrombosis, we have
generated transgenic mice overexpressing the human P2X1
receptor in the megakaryocytic cell lineage [150]. Platelets
from transgenic mice exhibited a gain of P2X1 ionotropic
activity as determined by more prominent P2X1-mediated
Ca2+ influx and platelet shape change. P2X1 overexpression
enhanced platelet secretion and aggregation evoked by low
doses of collagen, convulxin, or the thromboxane A2 mi-
metic U46619. In contrast, transgenic platelet responses to
ADP or thrombin were normal. Perfusing whole blood from
transgenic mice over collagen fibers at a shear rate of 1000 s -
1 resulted in increased P2X1-dependent aggregate formation
and phosphatidylserine exposure. Platelet hyperreactivity to
collagen was correlated with upregulated extracellular sig-
nal-regulated kinase 2 (ERK2) phosphorylation. Accord-
ingly, the MEK1/2 inhibitor U0126 potently inhibited the
collagen-induced aggregation of transgenic platelets, either
stirred or when perfused over a collagen surface. In a vis-
cometer, shear stress caused potent aggregation of transgenic
platelets in conditions where wild-type platelets did not ag-
gregate. In an in vivo model of thromboembolism consisting
of intravenous injection of a low dose of collagen plus
adrenaline, transgenic mice died more readily than wild-type
mice. Preinjection of U0126 not only fully protected trans-
genic mice against thrombosis, but also enhanced the sur-
vival of wild-type mice injected with a higher collagen dose.
In agreement with our findings, the analysis of P2X1-
deficient mouse platelets [151] showed decreased collagen-
induced aggregation and secretion; adhesion and thrombus
growth on a collagen-coated surface was also reduced, par-
ticularly when the wall shear rate was elevated. The mortal-
ity of P2X1-deficient mice in a model of systemic throm-
boembolism was reduced and the size of mural thrombi
formed after a laser-induced vessel wall injury was de-
creased as compared with normal mice, whereas the time for
complete thrombus removal was shortened.
Both studies (P2X1 overxpressing mice and P2X1-
deficient mice) thus indicate that the P2X1 receptor contrib-
utes to the formation of platelet thrombi, particularly in con-
ditions in which shear forces are high.
Owing to the lack of selective platelet P2X1 antagonists
and because of the rapid desensitization of this receptor dur-
ing platelet preparation, it had been difficult to analyze the
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contribution of this receptor to platelet function. Hence,
these animal models demonstrate in vivo a role for P2X1 in
hemostasis and thrombosis.
Mice overexpressing the platelet P2Y1 receptor have
been generated [152]. Platelets from these mice displayed
hyper-reactivity in vitro, as reflected by increased aggrega-
tion and induction of the release reaction in response to
ADP. Platelet hyper-reactivity was also apparent in vivo:
bleeding times were shortened and platelet counts were de-
creased following infusion of collagen and adrenaline. The
increased platelet reactivity of either P2X1 or P2Y1 overex-
pressing transgenic platelets highlights the positive contribu-
tion of both ATP and ADP to platelet activation. In addition,
it implies that controlled expression of the P2X1 and P2Y1
receptor genes is important for normal platelet activation.
Whether variable expression levels of these receptors exist in
humans and whether this might play a role in thrombotic
states remains to be assessed.
Low concentrations of apyrase (a soluble ATP-diphos-
phohydrolase (EC 3.6.1.5) catalysing the conversion of ATP
into ADP, and ADP into AMP) [153] are widely used during
the preparation of washed platelet samples, and it was found
to be necessary to preserve P2Y1 receptor functionality dur-
ing blood handling. More importantly, due to rapid desensi-
tization of P2X1 by spontaneously released ATP, a high con-
centration of apyrase is often required to demonstrate P2X1
function. Working with human and murine platelets, the
presence of apyrase is necessary to detect a,b- meATP-
induced Ca2+ influx and platelet shape change.
Fig. (4). Model depicting the role of P2X1 during platelet activation by low doses of collagen. Glycoprotein VI activation by collagen leads
to early protein kinase C- and MLC kinase-dependent degranulation. Rapidly released ATP triggers P2X1–mediated Ca2+ influx, activating
ERK2, in turn amplifying platelet secretion by reinforcing the early MLC kinase activation leading to increased MLC phosphorylation, fur-
ther granule release and platelet aggregation.
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Besides this protective function, the presence of apyrase
leads to simultaneous degradation of actively secreted ATP
and ADP, which interferes with the amplification of ongoing
platelet activation, explaining the well-described inhibitory
effects of apyrase. Therefore, the use of apyrase for in vitro
studies always constitutes a compromise between receptor
protection and simultaneous ligand breakdown.
In vivo experiments in mouse models, where endogenous
ecto-ATPases prevent receptor desensitization, are thus nec-
essary to confirm the conclusions of the in vitro analyses and
to demonstrate a physiological role for platelet P2 receptors.
This point is even more important if we consider that
already nanomolar ATP concentrations can obscure P2X1
receptor responses by driving a significant fraction of the
receptor pool into a long-lasting refractory closed state [118,
123]. Thus, we must keep in mind that P2X1-mediated re-
sponses studied in vitro may not reflect correctly the in vivo
situation.
CONCLUSIONS
Over the last eight years, the identification and detailed
characterization of the platelet P2Y receptors for ADP have
revealed new targets for the development of antithrombotic
drugs. Whether the P2X1 receptor represents a potential tar-
get for antithrombotic therapy remains an open question.
Even though compounds like MRS2159 has shown some
efficacy to selectively antagonize P2X1 in washed human
platelet suspensions, the ability of most available P2X-
subtype selective antagonists to inhibit platelet function has
still to be defined.
Mice deficient for the three P2 receptors identified on
platelets as well as transgenic mice overexpressing platelet
P2X1 and P2Y 1 receptors now exist. The combined analyses
of these animal models should help to further understand
how P2X and P2Y receptors contribute to platelet function in
vivo, and should provide insights on the physiological action
of ATP versus ADP at these receptors.
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ABBREVIATIONS
a,b -meATP = a,b -methylene ATP
b,g -meATP = b,g -methylene ATP
ERK = Extracellular signal-regulated kinase
MAPK = Mitogen-activated protein kinase
2MeS-ADP = 2-methylthio-ADP
MLCK = Myosin light chain kinase
PI-3K = Phosphoinositide 3-kinase
PLC = Phospholipase C
PPADS = Pyridoxal-5’-phosphate 6-azophenyl-2’, 5’-
disulfonate
TF = Tissue factor
VWF = Von Willebrand factor
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